Skip to main content
. 2022 Aug 4;12:969787. doi: 10.3389/fonc.2022.969787

Figure 1.

Figure 1

CD44 in the TME is required for glioma cell migration. (A, B) Mouse and human established glioma cell lines were assessed for their ability to invade in the absence of CD44 from the TME. Ex-vivo cultured brain slices were prepared from WT and CD44-/- mice. GL261, SMA560, tNSC3 mouse glioma cells and LN319, U87MG, LN229 human glioma cells were seeded in an 1% low melting agar-coated 96-well plate and allowed to form spheroids, which were then implanted into the brain slices. (A) Representative images of DiD (lipophilic carbocyanine dye) labeled glioma spheroids 48 hours after implantation, scale bar 100μm. (B) The number of invading spheroids was counted for each cell line and presented as percentage of total counted spheroids. Bar charts represent the percentage of invading spheroids from at least 3 experiments. An average of 10-20 spheroids were evaluated per experiment. Two-way ANOVA with Sidak’s multiple comparisons test, ****p < 0.0001. (C, D) Spheroids of mouse (DKO11804) of human (NMA59) primary glioma cells were implanted into organotypic brain slices from WT and CD44-/- mice. (C) Representative images of DiD labeled glioma spheroids 48 hours after implantation, scale bar 100μm. (D) Quantification of the number of invading spheroids (n≥3 experiments, 10-20 spheroids per experiment). Bar charts represent the relative percentage of invading spheroids for each cell line and mouse genotype. Two-way ANOVA with Sidak’s multiple comparisons test, **p < 0.01; ****p < 0.0001.